表紙:ヒト・パピローマウイルスE6タンパク質:パイプライン製品の分析
市場調査レポート
商品コード
368720

ヒト・パピローマウイルスE6タンパク質:パイプライン製品の分析

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2019

出版日: | 発行: Global Markets Direct | ページ情報: 英文 114 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.49円
ヒト・パピローマウイルスE6タンパク質:パイプライン製品の分析
出版日: 2019年12月27日
発行: Global Markets Direct
ページ情報: 英文 114 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、ヒト・パピローマウイルスE6タンパク質を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

ヒト・パピローマウイルスE6タンパク質 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Abion Inc
  • BioNTech AG
  • Cancer Research Technology Ltd
  • Etubics Corp
  • Genexine Inc
  • Hookipa Biotech AG
  • Inovio Pharmaceuticals Inc
  • MedImmune LLC
  • Rottapharm Biotech Srl
  • Selecta Biosciences Inc
  • Tomegavax Inc
  • Transgene SA

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Abion Inc, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Pipeline by BioNTech SE, H2 2019
  • Pipeline by Cellid Co Ltd, H2 2019
  • Pipeline by Etubics Corp, H2 2019
  • Pipeline by Genexine Inc, H2 2019
  • Pipeline by Hookipa Pharma Inc, H2 2019
  • Pipeline by Immunomic Therapeutics Inc, H2 2019
  • Pipeline by Innovene, H2 2019
  • Pipeline by Inovio Pharmaceuticals Inc, H2 2019
  • Pipeline by Ispin Inc, H2 2019
  • Pipeline by Papivax LLC, H2 2019
  • Pipeline by Rottapharm Biotech Srl, H2 2019
  • Pipeline by Selecta Biosciences Inc, H2 2019
  • Pipeline by Touchlight Genetics Ltd, H2 2019
  • Pipeline by Transgene SA, H2 2019
  • Pipeline by UbiVac LLC, H2 2019
  • Pipeline by ViciniVax BV, H2 2019
  • Pipeline by Vir Biotechnology Inc, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
目次
Product Code: GMDHC2104TDB

Summary

Human Papillomavirus Protein E6 (E6) pipeline Target constitutes close to 34 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The latest report Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2019, outlays comprehensive information on the Human Papillomavirus Protein E6 (E6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular transformation. It acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1-91. The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 3, 1, 9 and 2 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 6 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health, Infectious Disease and Gastrointestinal which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Human Papillomavirus Infections, Penile Cancer, Anal Cancer, Head And Neck Cancer, Oropharyngeal Cancer, Vaginal Cancer, Vulvar Cancer, Anal Dysplasia, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Pancreatic Cancer and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)
  • The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Human Papillomavirus Protein E6 (E6) - Overview
  • Human Papillomavirus Protein E6 (E6) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development
  • Abion Inc
  • AstraZeneca Plc
  • BioNTech SE
  • Cellid Co Ltd
  • Etubics Corp
  • Genexine Inc
  • Hookipa Pharma Inc
  • Immunomic Therapeutics Inc
  • Innovene
  • Inovio Pharmaceuticals Inc
  • Ispin Inc
  • Papivax LLC
  • Rottapharm Biotech Srl
  • Selecta Biosciences Inc
  • Touchlight Genetics Ltd
  • Transgene SA
  • UbiVac LLC
  • ViciniVax BV
  • Vir Biotechnology Inc
  • Human Papillomavirus Protein E6 (E6) - Drug Profiles
  • (bizalimogene ralaplasmid + mavilimogene ralaplasmid) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer